Also known as: GPCRs
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.
Barcelona-based Pharmacelera closed a €6 million funding round led by Heran Partners to establish a U.S. presence and expand its quantum mechanics and AI-powered drug discovery platform.
Three new computational approaches enhance molecular property prediction and drug design through advanced neural networks, multimodal learning, and thermodynamic analysis of receptor-ligand interactions.
Artificial intelligence is increasingly used to analyze Alzheimer's datasets and inform drug discovery, while researchers identify promising new drug targets including the IDOL enzyme and somatostatin receptors that could lead to more affordable treatments.
